DelveInsight’s “Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Retinal Vein Occlusion, historical and forecasted epidemiology as well as the Retinal Vein Occlusion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Retinal Vein Occlusion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Retinal Vein Occlusion Market Forecast
Some of the key facts of the Retinal Vein Occlusion Market Report:
- The Retinal Vein Occlusion market size was valued approximately USD 2,378 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- There were about 2,708,118 cases of Retinal Vein Occlusion overall in the 7MM in 2021; this number is predicted to rise to 2032 at a CAGR of 1.0% for the research period (2019-2032)
- Germany had the greatest prevalence of Retinal Vein Occlusion cases among the EU-5 nations in 2021 (about 225,397 cases), with a predicted rise by 2032. In Spain, the least amount of cases were reported
- Retinal Vein Occlusion was diagnosed in roughly 1,518,208 cases overall in the 7MM in 2021; this number is expected to rise by 2032 at a CAGR of 1.4% over the course of the study period (2019-2032)
- In the 7MM, there were roughly 715,167 diagnosed cases of Retinal Vein Occlusion in males and 803,041 diagnosed cases in females in the year 2021. These cases are anticipated to rise by 2032, according to the report
- Retinal Vein Occlusion occurs more frequently in people who are older. For the age groups under 65, 65 to 74, and 75 years, the age-specific diagnosed prevalent cases in the 7MM were roughly 454,378, 572,552, and 491,279 cases in 2021
- Key Retinal Vein Occlusion Companies: Novartis, Allergan, Eyetech Pharma, Aerpio Therapeutics, Emmes Company, LLC, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences, Roche, Chugai Pharmaceuticals, and others
- Key Retinal Vein Occlusion Therapies: ranibizumab, dexamethasone implant, pegaptanib sodium, AKB-9778, aflibercept, TLC399, AR-1105, GB-102, ONS-5010 (Lytenava), KSI-301, Vabysmo (faricimab), and others
- The Retinal Vein Occlusion epidemiology based on type-specific cases analyzed that the type-specific distribution of RVO suggests a higher prevalence of BRVO than CRVO
- The Retinal Vein Occlusion market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Retinal Vein Occlusion pipeline products will significantly revolutionize the Retinal Vein Occlusion market dynamics.
Retinal Vein Occlusion Overview
After diabetic retinopathy, retinal vein occlusion (RVO) is the second most prevalent retinal vascular condition. It is characterized by thrombus formation in the central, hemi-central, or branch retinal veins. The neighboring atherosclerotic retinal arteries’ compression is the most frequent etiological cause. External compression or diseases of the venous wall, such as vasculitis, are additional potential reasons.
Get a Free sample for the Retinal Vein Occlusion Market Report
https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
Retinal Vein Occlusion Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Retinal Vein Occlusion Epidemiology Segmentation:
The Retinal Vein Occlusion market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Retinal Vein Occlusion
- Prevalent Cases of Retinal Vein Occlusion by severity
- Gender-specific Prevalence of Retinal Vein Occlusion
- Diagnosed Cases of Episodic and Chronic Retinal Vein Occlusion
Download the report to understand which factors are driving Retinal Vein Occlusion epidemiology trends @ Retinal Vein Occlusion Epidemiology Forecast
Retinal Vein Occlusion Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Retinal Vein Occlusion market or expected to get launched during the study period. The analysis covers Retinal Vein Occlusion market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Retinal Vein Occlusion Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Retinal Vein Occlusion Therapies and Key Companies
- ranibizumab: Novartis
- dexamethasone implant: Allergan
- pegaptanib sodium: Eyetech Pharma
- AKB-9778: Aerpio Therapeutics
- aflibercept: Emmes Company, LLC
- TLC399: Taiwan Liposome Company
- AR-1105: Aerie Pharmaceuticals
- GB-102: Graybug Vision
- ONS-5010 (Lytenava): Outlook Therapeutics
- KSI-301: Kodiak Sciences
- Vabysmo (faricimab): Roche/Chugai Pharmaceuticals
Discover more about therapies set to grab major Retinal Vein Occlusion market share @ Retinal Vein Occlusion Treatment Market
Retinal Vein Occlusion Market Drivers
- Rich Retinal Vein Occlusion pipeline
- Advancement in drug therapies
- Increase in knowledge and awareness
- Increasing prevalence of Retinal Vein Occlusion
Retinal Vein Occlusion Market Barriers
- Cost Consciousness
- Risk and complications
- Lack of focus on for visual restoration
- Failure of investigational drugs
- Invasion of biosimilar in future
Scope of the Retinal Vein Occlusion Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Retinal Vein Occlusion Companies: Novartis, Allergan, Eyetech Pharma, Aerpio Therapeutics, Emmes Company, LLC, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences, Roche, Chugai Pharmaceuticals, and others
- Key Retinal Vein Occlusion Therapies: ranibizumab, dexamethasone implant, pegaptanib sodium, AKB-9778, aflibercept, TLC399, AR-1105, GB-102, ONS-5010 (Lytenava), KSI-301, Vabysmo (faricimab), and others
- Retinal Vein Occlusion Therapeutic Assessment: Retinal Vein Occlusion current marketed and Retinal Vein Occlusion emerging therapies
- Retinal Vein Occlusion Market Dynamics: Retinal Vein Occlusion market drivers and Retinal Vein Occlusion market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Retinal Vein Occlusion Unmet Needs, KOL’s views, Analyst’s views, Retinal Vein Occlusion Market Access and Reimbursement
To know more about Retinal Vein Occlusion companies working in the treatment market, visit @ Retinal Vein Occlusion Clinical Trials and Therapeutic Assessment
Table of Contents
1. Retinal Vein Occlusion Market Report Introduction
2. Executive Summary for Retinal Vein Occlusion
3. SWOT analysis of Retinal Vein Occlusion
4. Retinal Vein Occlusion Patient Share (%) Overview at a Glance
5. Retinal Vein Occlusion Market Overview at a Glance
6. Retinal Vein Occlusion Disease Background and Overview
7. Retinal Vein Occlusion Epidemiology and Patient Population
8. Country-Specific Patient Population of Retinal Vein Occlusion
9. Retinal Vein Occlusion Current Treatment and Medical Practices
10. Retinal Vein Occlusion Unmet Needs
11. Retinal Vein Occlusion Emerging Therapies
12. Retinal Vein Occlusion Market Outlook
13. Country-Wise Retinal Vein Occlusion Market Analysis (2019–2032)
14. Retinal Vein Occlusion Market Access and Reimbursement of Therapies
15. Retinal Vein Occlusion Market Drivers
16. Retinal Vein Occlusion Market Barriers
17. Retinal Vein Occlusion Appendix
18. Retinal Vein Occlusion Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services